IGF1R and small cell lung carcinoma: In in vitro studies, different IGF-1R inhibiting substances have led to additive and synergistic effects when combined with cisplatin, e.g. the IGF-1R antibodies MK-0646 in endometrial carcinoma and R1507 in small cell lung cancer [70,71].